MD DI’s Post

🚨Breaking —> Dawn Health and Novartis Launch Ekiva-MS DTx App for Multiple Sclerosis>> 🧠Dawn Health, in partnership with Novartis, has released Ekiva-MS, an app designed to assist individuals living with multiple sclerosis (MS), launching first in Germany 🧠The Ekiva-MS app launches with the goal of enhancing patients' empowerment in managing their chronic MS care, providing support in remote, at-home settings 🧠The app, cocreated with patients, offers patients additional insights into their disease activity, aiming to enable shared decision making with their healthcare providers (HCPs) thus optimizing care and improving the quality of consultations. 🧠Ekiva-MS aims to address the highly individual and unpredictable nature of MS, facilitating personalized care and helping to reduce uncertainty and concern between HCP interactions. 🧠Core components of the app include symptom and quality of life tracking, passive data collection, and digital biomarkers to give a comprehensive overview of each individual's experience with MS 👇Link to press release and website in comments below #digitalhealth #DTx #pharma

📚 Happy to share that our paper "Exploring Semaglutide's Impact on Lean Mass: Insights from Clinical Trials" is now published! 🎉Foteini Dermiki, Michail Penteris, Christos A Kontogiorgis 🔍 Semaglutide has made a significant appearance in the healthcare world, offering promising benefits for various conditions. Our investigation into its effects on lean mass sheds light on its potential implications for patient care. 🔗 Read the full paper here [https://lnkd.in/ddUAxEK6] 🙌 #Research #Semaglutide #Healthcare

🌏 Today is #WorldCancerDay, an opportunity to raise awareness and focus on improving healthcare access for cancer patients. Every year, there are approximately 734,000 new cases of cancer diagnosed all over the world. Moreover, the World Health Organization forecasts a nearly 50% increase in this number by 2040. 🤕 Cancer-associated diseases represent a continuous burden, causing significant physical, emotional, and financial stress on individuals, families, and communities. This is why 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗲𝗮𝗿𝗹𝘆 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 are essential for improving patient outcomes. Further research on 𝗹𝗲𝘀𝘀 𝗶𝗻𝘃𝗮𝘀𝗶𝘃𝗲, 𝗮𝗻𝗱 𝗺𝗼𝗿𝗲 𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗽𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗺𝗲𝘁𝗵𝗼𝗱𝘀 is essential to overcome the challenges of cancer screening. Spanish companies, such as Amadix and Testeavida, are working to integrate 𝗱𝗶𝗴𝗶𝘁𝗮𝗹 𝗵𝗲𝗮𝗹𝘁𝗵 for diagnosis improvements and more personalized and effective treatment options. 🔎✨ 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘀𝗼𝗺𝗲 𝗼𝗳 𝘁𝗵𝗲𝘀𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗿𝗲𝗲𝗹. What is your biggest challenge when conducting healthcare campaigns? 𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝘂𝘀 𝗳𝗼𝗿 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗰𝗮𝗺𝗽𝗮𝗶𝗴𝗻𝘀 👉 #MedicalWriting #MedComms #MedCommsAgency #Pharma #Biotech #Healthcare #Health #Medicine #Entrepreneurship #Innovation #Biomedicine #ResearchImpact #MedicalCopywriting #WorldCancerDay #DigitalHealth

Our latest white paper explores the strategic insights and global perspectives enhancing medical tourism for oncology. GRG Health's study reveals why patients opt for treatment abroad, emphasizing cost-effectiveness, superior care quality, and access to cutting-edge therapies. These insights are crucial for healthcare providers aiming to meet the complex needs of international patients and develop targeted marketing strategies. This resource is essential for optimizing service offerings and improving patient satisfaction in this rapidly evolving sector. #MedicalTourism #OncologyCare #GlobalHealthcare #PatientSatisfaction #HealthcareInnovation

A 24-year-old woman has had increasing malaise; facial skin lesions exacerbated by sunlight exposure; and arthralgias and myalgias for the past month. On physical examination she has mild pedal edema and erythematous malar rash. On auscultation, a friction rub is audible over the chest. Laboratory findings include pancytopenia and serum creatinine 3 mg/dL. Urinalysis shows hematuria and proteinuria. A serologic test for syphilis yields a false-positive result. A renal biopsy shows granular deposits of IgG and complement in the mesangium and along the basement membrane. Which of the following mechanisms is most likely involved in the pathogenesis of her disease? Antiphospholipid antibodies Defective clearance of apoptotic nuclei Increased production of IFN-γ Molecular mimicry Explanation: Defective clearance of apoptotic nuclei This young woman has a classic picture of systemic lupus erythematosus (SLE)—the erythematous malar facial skin rash, and renal failure with proteinuria and hematuria from immune complex deposition in the glomeruli.  A fundamental defect in SLE is the failure of mechanisms that maintain self-tolerance. Defective clearance and hence increased burden of nuclear apoptotic bodies leading to formation of increased quantities and immunogenic forms of nucleic acids, their accompanying proteins and other self-antigens is considered as the main mechanism that underlies SLE. This finally gives rise to the pathogenic DNA–anti-DNA immune complexes, as measured by the antinuclear antibody test. Antiphospholipid antibodies may be present with SLE but lead to coagulopathy. IFN-γ is a product of CD4 T cells and NK cells. There is no evidence of delayed hypersensitivity or NK cell dysfunction in SLE. Molecular mimicry occurs when a microbial antigen cross-reacts with normal tissue, as in rheumatic fever. Widespread and nonspecific activation of T cells by superantigen occurs in toxic shock syndrome.

🚀 Discover the Future of #Diabetes #Care: Who's Leading the Change? 🌟 Exciting news from Digital Oxygen! We've just released our latest exploration into the cutting-edge companies improving and innovating #diabetes #management in our 2024 Advanced Diabetes Technology Landscape. This year, we're showcasing over 250 companies, marking a remarkable 25% growth versus 2023. 🔍  Dive into a world where #technology meets Diabetes Care, with our report categorizing 13 key segments for advanced Diabetes therapy. From insulin pump innovators and CGM sensor developers to patient-centric apps and breakthrough AID software, we've covered it all. 👀 Highlights that caught my eye: AID Technology: Once a vision, now the standard. Automated Insulin Delivery is transforming lives of patients – on a day-to-day basis with companies like Diabeloop, CamDiab or Tidepool. The CGM Revolution: Dominated by leaders like Abbott, Dexcom Inc., and Medtronic, yet vibrantly growing with new entrants poised to innovate like Roche Diabetes Care, Sinocare Inc. or SiBionics. Non-Invasive Measurement: Big names like Apple and Samsung Electronics are on the brink of breakthroughs, signaling a surge in the non-invasive sector with others innovators like BOYDSense, Lifecare or KnowLabs – however, no products launched yet. 📲 Craving more insights? Grab your free copy of the Advanced Diabetes Technology Landscape from our homepage and see what companies like Diabetes Technology heavy weights Ypsomed AG, Insulet Corporation, Tandem Diabetes Care, embecta or MENARINI Group are offering today and tomorrow – but also more software-focussed companies like Glooko, Sidekick Health Germany (formerly aidhere) , Hedia, SNAQ AG, DDM Health or OneTwo Analytics. And what are Novo Nordisk, Sanofi or Eli Lilly and Company planning with regards to Diabetes Technology? Link in the comments! 💡 Let's spark a conversation! Missing a company in our report, or hungry for more details on the future of Diabetes Technology and how to be successful in that market? I'll be at the upcoming Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, ready to dive deep into these discussions. Drop me a message, and let's schedule a chat. Let's engage, share, and innovate together for a healthier tomorrow. #DiabetesCare #DigitalHealth #Innovation #ATTD #HealthTech #DiabetesManagement